£2.6M
The pre-seed round was co-led by IQ Capital and Ahren Innovation Capital to support team expansion and technology validation.
"Our ability to take a sample from someone with an unknown infection and answer the open question 'what do they have?' within a minute is a gamechanger for infection diagnosis and treatment. We’ll start with respiratory viruses and expand from there. In parallel, we’ll be simplifying the workflow to move the test from the lab to point of care, which will represent a step change in the availability and cost of infectious disease diagnostics worldwide."
IQ Capital + 2 others
